

Ref. No: 0830
Date: 03/04/24
Subject: Dermatology Treatments

REQUEST

1. I am analysing the treatment of dermatological conditions in the UK. Could you please provide the number of patients treated in the last 4 months, by the dermatology department, with each of the following products:

- Abrocitinib
- Baricitinib
- Dupilumab
- Lebrikizumab
- Tralokinumab
- Upadacitinib

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. I am analysing the treatment of dermatological conditions in the UK. Could you please provide the number of patients treated in the last 4 months, by the dermatology department, with each of the following products?

Treatment	No. Patients
Abrocitinib	0
Baricitinib	7
Dupilumab	92
Lebrikizumab	0
Tralokinumab	<5
Upadacitinib	7

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such

circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.